CHARACTERISTICS OF SOMATOSTATIN DESENSITIZATION IN THE PITUITARY TUMOR CELL LINE ATT-20

May 28th, 2008 by admin

N Mahy, M Woolkalis, D Manning and T Reisine

Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia.

The molecular mechanisms of somatostatin (SRIF) desensitization were investigated in the anterior pituitary tumor cell line AtT-20. Previous studies have shown that pretreatment of AtT-20 cells with SRIF analogs desensitizes the cells to SRIF inhibition of hormone release, cyclic AMP formation and calcium influx. This desensitization may involve a change in the properties of the SRIF receptors. Pretreatment of AtT-20 cells with Trp8-SRIF reduced the binding of the SRIF analog [125I]CGP 23996 (des-Alal, Gly2-[desamino-Cys3, Tyr11]-3, 14-dicarbasomatostatin) to AtT-20 cell membranes. The loss of [125I]CGP 23996 binding was dependent on the time of Trp8-SRIF treatment and was reversible. The ability of GTP analogs to inhibit [125I]CGP 23996 binding was reduced after Trp8-SRIF treatment, suggesting that the SRIF receptor and the inhibitory G proteins become uncoupled during desensitization. This is indicated further by the decrease in SRIF stimulation of GTPase activity and SRIF inhibition of forskolin-stimulated adenylyl cyclase activity in desensitized membranes. The reduction and recovery of SRIF inhibition of adenylyl cyclase activity after Trp8-SRIF pretreatment has a similar time course as the changes in [125I]CGP 23996 binding. GTP inhibition of forskolin-stimulated adenylyl cyclase activity is also reduced in SRIF-desensitized membranes. The loss of the GTP effect occurs rapidly and does not fully recover after Trp8-SRIF pretreatment. The levels of ADP-ribosylation of inhibitory GTP binding protein, the relative quantity of the alpha subunits of the inhibitory G proteins and their electrophoretic mobility after 2-dimensional gel electrophoretic analysis, are not altered in SRIF-desensitized membranes.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 247, Issue 1, pp. 390-396, 10/01/1988

Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics

Posted in CHARACTERISTICS OF SOMATOSTATIN DESENSITIZATION IN THE | No Comments »

WHY IT IS DONE

May 28th, 2008 by admin

A test for prolactin is done:

  • To find the cause of abnormal nipple discharge, or if a woman is not having periods (amenorrhea) or if a woman is having a hard time becoming pregnant .
  • In a man when a pituitary gland problem is suspected. Also, a prolactin test may be done to check levels if a man lacks sexual desire or if he has a hard time having an erection . Prolactin levels may be checked when a man’s testosterone levels are really low.
  • To see whether a tumor in the pituitary gland (called a prolactinoma) is making large amounts of prolactin.

How To Prepare

Do not eat or drink for a certain number of hours as instructed by your health professional before having a prolactin test.

A blood prolactin test is usually done about 3 hours after you wake up, sometime between 8 a.m. and 10 a.m.

Emotional stress or strenuous exercise just before the test can raise prolactin levels. You may be asked to rest quietly for up to 30 minutes before having your blood drawn.

Stimulation of the nipples can raise prolactin levels. Avoid nipple stimulation for 24 hours prior to prolactin testing. A woman having abnormal nipple discharge should not do anything to cause more discharge before the test.

How It Is Done

The health professional drawing blood will:

  • Wrap an elastic band around your upper arm to stop the flow of blood. This makes the veins below the band larger so it is easier to put a needle into the vein.
  • Clean the needle site with alcohol.
  • Put the needle into the vein. More than one needle stick may be needed.
  • Hook a tube to the needle to fill it with blood.
  • Remove the band from your arm when enough blood is collected.
  • Put a gauze pad or cotton ball over the needle site as the needle is removed.
  • Put pressure to the site and then a bandage.

How It Feels

The blood sample is taken from a vein in your arm. An elastic band is wrapped around your upper arm. It may feel tight. You may feel nothing at all from the needle, or you may feel a quick sting or pinch.

Risks

There is very little chance of a problem from having blood sample taken from a vein.

Risks of a blood test

  • You may get a small bruise at the site. You can lower the chance of bruising by keeping pressure on the site for several minutes.
  • In rare cases, the vein may become swollen after the blood sample is taken. This problem is called phlebitis. A warm compress can be used several times a day to treat this.
  • Ongoing bleeding can be a problem for people with bleeding disorders. Aspirin, warfarin (Coumadin), and other blood-thinning medicines can make bleeding more likely. If you have bleeding or clotting problems, or if you take blood-thinning medicine, tell your doctor before your blood sample is taken.

Results

A prolactin test measures the level of the hormone prolactin, which is made by the pituitary gland, in your blood. Prolactin levels are different throughout the day. The highest levels occur during sleep and shortly after you wake up.

Normal

Normal values may vary from lab to lab.

Prolactin

Nonpregnant women

Less than 25 nanograms per milliliter (ng/mL) or 25 mcg/L (SI units)

Men

Less than 20 ng/mL or 20 mcg/L (SI units)

Pregnant women

20 to 400 ng/Ml or 20 to 400 mcg/L (SI units)

High values

  • High levels of prolactin (usually higher than 200 ng/mL) may mean a pituitary gland tumor (prolactinoma) is present. The higher the prolactin level, the more likely a pituitary gland tumor is present. If a prolactin level is over 200 ng/mL, a magnetic resonance imaging (MRI) test may be done to confirm a pituitary tumor is present. A normal or low prolactin level does not always mean there is no pituitary tumor. An MRI test may be done if a pituitary tumor is suspected.
  • High levels of prolactin may mean that the pituitary gland is making excess prolactin for unknown reasons (idiopathic hyperprolactinemia).
  • Other conditions that can cause high prolactin levels include pregnancy, liver disease (cirrhosis), kidney disease, and hypothyroidism.

Many conditions can affect prolactin levels. Your health professional will talk with you about any abnormal results in relation to your symptoms and medical history.

What Affects the Test

Reasons you may not be able to have the test or why the results may not be helpful include:

  • Having a lot of emotional stress or doing strenuous exercise before the test.
  • Trouble sleeping. Prolactin levels are highest during sleep so if you do not sleep well, your levels may be lower than normal.
  • Stimulating your nipples.
  • Taking certain medicines, such as birth control pills, high blood pressure medicines, tricyclic antidepressants, or medicines for mental illness, such as phenothiazines.
  • Using cocaine.
  • Having a test with radioactive tracer a week before the prolactin test.

What To Think About

  • Men and nonpregnant women normally have low levels of prolactin. The only known problem caused by a lack of prolactin is not being able to make milk after pregnancy. Therefore, even people who have an abnormally low level of prolactin are not treated for the condition.
  • Men may have a prolactin test if a man lacks sexual desire or if he has a hard time having an erection (erectile dysfunction). Prolactin levels may be checked when a man’s testosterone levels are really low. For more information, see the medical test Testosterone.
  • Treatment for a pituitary gland tumor that is making too much prolactin includes medicines (such as bromocryptine), removing the pituitary gland, or radiation therapy to the gland. The choice of treatment is based on the size of the tumor and the health and age of the person being treated.

References

Other Works Consulted

·         Chernecky CC, Berger BJ, eds. (2004). Laboratory Tests and Diagnostic Procedures, 4th ed. Philadelphia: Saunders.

·         Fischbach FT, Dunning MB III, eds. (2004). Manual of Laboratory and Diagnostic Tests, 7th ed. Philadelphia: Lippincott Williams and Wilkins.

Pagana KD, Pagana TJ (2006). Mosby’s Manual of Diagnostic and Laboratory Tests, 3rd ed. St. Louis: Mosby.

Posted in WHY IT IS DONE | No Comments »

FAQ’S

May 28th, 2008 by admin

1.  What causes a pituitary tumor to develop?

Pituitary tumors are common. In autopsy studies of patients who did not have known pituitary disease, as many as 26% had a small tumor (adenoma) in the gland. Molecular biology studies have shown that a change in the DNA of pituitary cells can cause unregulated growth of a particular cell type resulting in a pituitary tumor, called an adenoma. There are no known environmental causes. Very uncommonly, pituitary tumors may be inherited. In most of these patients, there is usually a family history of other endocrine (parathyroid or pancreas) tumors or of dark skin spots and skin and heart tumors), though in a few, there may be only pituitary tumors.

2. Is a pituitary tumor a brain tumor?

The pituitary gland is NOT in the brain and pituitary tissue is different from brain tissue. Since the pituitary gland is located at the base of the brain and is connected to the brain by a thin stalk, there is often confusion, particularly by insurance companies, about the classification of a pituitary tumor. A pituitary tumor is NOT a brain tumor.

3. Is a pituitary tumor cancer?

No, in over 99% of patients, this is NOT a cancer; it is benign. Although the tumor is benign, it can cause problems because of its size, because it causes the normal pituitary gland to become underactive (hypopituitarism) or because of excessive hormone production by the tumor.

4. What are the symptoms of a pituitary tumor?

The symptoms of a pituitary tumor depend on two issues: 1) the size and location of the tumor (tumor mass effects), and 2) whether or not the tumor is producing too much or too little hormone (endocrine function). When a tumor is large enough to compress the optic chiasm (where the optic [eye] nerves come together) there may be loss of vision, particularly peripheral vision. Very occasionally tumors may cause double vision. Headache may also occur; the type of headache varies from patient to patient. Headache may occur with a large or a small tumor.

Some tumors overproduce hormones. The most common of these is a prolactin producing tumor (prolactinoma), followed in frequency by growth hormone producing tumors (acromegaly) and the by ACTH tumors (Cushing’s disease) and rare TSH producing tumors. The overproduction of these hormones causes specific problems (see below and refer to sections on acromegaly and prolactinoma and any articles on these tumors). A tumor may also interfere with normal pituitary function and cause hypothyroidism (low thyroid hormone level), adrenal insufficiency (low cortisol level), hypogonadism (loss of sexual function in men, loss of menstrual periods or fertility problems in women). Very rarely, a pituitary tumor causes diabetes insipidus, which results in frequent urination and excessive thirst. Diabetes insipidus is not high blood sugar levels; it is a problem with the ability of the kidney to retain fluid because of a deficiency of the pituitary hormone, vasopressin (also called antidiuretic hormone). When related to a pituitary tumor diabetes insipidus comes on after an operation to remove the pituitary tumor. Most often diabetes insipidus is related to other another sort of tumor (craniopharyngioma).

Specific types of tumors cause various symptoms and changes in body function.

Prolactinoma: most commonly causes loss of sexual function and infertility in men. Men may also have a breast discharge that looks like milk or occasionally enlargement of the breasts. In women of reproductive age a prolactin-producing tumor may cause milk in the breasts, a change in menstrual periods or loss of menses or infertility. Women who have gone through menopause do not have a change in menstrual periods to signal the problem; in this situation, headache and loss of vision may be the first indicator of a prolactinoma. There can sometimes be impairment of pituitary function leading to growth hormone deficiency, hypothyroidism and adrenal insufficiency as well as the sexual dysfunction referred to above.

Acromegaly: Enlargement of the hands and feet and coarsening of facial features and excessive sweating are the most common features of excessive growth hormone production. Other problems that occur include joint pains and arthritis, sleep apnea (excessive snoring, stopping breathing during sleep and fatigue during waking hours), hypertension, diabetes mellitus (high blood sugar), colon polyps, change in teeth spacing, oily skin and acne. These tumors can also cause tumor mass effect and cause symptoms due to underproduction of hormones (hypothyroidism, adrenal insufficiency, impaired sexual function). Yes, the same tumor that overproduces one hormone may under produce others. Both of these can cause symptoms.

Cushing’s Disease : The term “Cushing’s Disease” refers to the overproduction of cortisol by the adrenal glands caused by a pituitary tumor producing an excessive amount of the pituitary hormone, ACTH. Dr. Harvey Cushing, a neurosurgeon, first described this condition in the 1920s. Excessive cortisol production causes weight gain (particularly in the abdomen and neck), loss of muscle mass (legs, arms) and muscle weakness, depression, difficulty with concentration and memory, sleep disturbance, irritability, thinning of the skin with easy bruising, hypertension, diabetes mellitus, loss of bone mass (osteoporosis) with a risk for bone fractures and weakening of the immune system with a higher risk of developing infections.

Thyroid stimulating hormone (TSH) Secreting Tumor : This is the least common type of hormone producing pituitary tumor. Excessive TSH stimulates the thyroid gland to enlarge (goiter) and also produce an excessive amount of thyroid hormone (hyperthyroidism). This kind of hyperthyroidism is caused by a pituitary tumor overproducing TSH (this is in contrast to the much more common type of hyperthyroidism (Grave’s disease) in which the problem is in the thyroid gland itself). In the latter the TSH is unmeasurably low in contrast to the TSH secreting tumor in which TSH is measurable or high. Symptoms of hyperthyroidism are similar in both kinds of hyperthyroidism and include weight loss, nervousness, rapid heartbeat, difficulty sleeping, frequent bowel movements and in women, less menstrual flow or loss of menstrual periods. As with other functioning pituitary tumors these can also cause symptoms due to the tumor size.

Non Secretory Tumor : This refers to a tumor that does not produce an excessive amount of a pituitary hormone that can be measured in a blood test. This type of tumor is usually discovered when patients develop visual field problems due to the size of the tumor. This type of tumor is usually detected after it has become large, causing loss of vision and/or headache. Frequently as these tumors get bigger the patients have a higher incidence of reduced pituitary function or hypopituitarism, most commonly in the form of sexual dysfunction in men and loss of regular menses and infertility in premenopausal women. Hypothyroidism (low thyroid hormone level) or adrenal insufficiency (low cortisol level) may occur due to partial or complete destruction of the normal cells of the pituitary gland. (See section on hypopituitarism for discussion).

Craniopharyngioma/Rathke’s Cleft Cyst : These tumors are congenital - a defect in the development of the pituitary gland which begins during fetal (in the womb) development. The beginnings of the tumor are present at birth but may not cause a problem until childhood or in adulthood until its size or relationship to important structures in that part of the head causes a problem. In fact, these tumors and cysts may never cause a problem. They are not, however, pituitary tumors. This is not a malignant (cancerous) tumor but it often interferes with normal pituitary function causing hypopituitarism (loss of pituitary function) or headache or loss of vision. This type of tumor commonly causes diabetes insipidus, frequent urination and excessive thirst (not diabetes or high blood sugar).

5. What are other pituitary diseases that can be mistaken for pituitary tumors?

Pituitary Cyst : Any endocrine gland may develop a cyst. This occurs commonly in the ovaries and thyroid gland; a cyst in the pituitary gland is benign (not cancer). Many pituitary cysts cause no symptoms and don’t grow or enlarge. Only when they do, do they become symptomatic. They can cause headache and/or rarely interfere with normal pituitary function. If the cyst is large, loss of vision may occur. The treatment for this problem depends upon the size of the cyst and its proximity to the optic chiasm. Often no treatment is necessary, but when necessary it is removed by surgery. There are no medical treatments for this problem.

Inflammatory Problems: A number of inflammatory problems can lead to either enlargement of the pituitary gland or infiltration into the pituitary or the pituitary stalk or the gland above the pituitary (Hypothalamus).

Lymphocytic hypophysitis is an inflammatory process (rather than a tumor) that can enlarge the pituitary gland and cause pituitary hormone insufficiency. It occurs mostly in women and is often related to a pregnancy. The symptoms can be profound. They include weakness, extreme fatigue, weight loss, and nausea to name a few. The latter symptoms are due to ACTH deficiency, which in turn causes adrenal gland insufficiency. Hypothyroid symptoms also occur and menstrual periods may be interfered with. Sometimes it is not possible to differentiate between hypophysitis and a pituitary tumor on MRI. The pituitary gland can enlarge to cause visual problems and severe headaches. When suspected some endocrinologists have treated these women with cortisone and in some patients the apparent tumor shrinks. Occasionally, there is spontaneous return of normal pituitary function.

Sarcoidosis is an inflammatory disease that usually affects the lungs. Granulomas are inflammatory deposits that have a particular appearance under the microscope. Sarcoidosis can also affect the pituitary gland and hypothalamus. This disease can cause Diabetes Insipidus because it can affect sensitive areas of the pituitary stalk or hypothalamus that control production of the hormone, vasopressin. It can also cause sexual dysfunction or loss of menstruation, hypothyroidism, adrenal insufficiency, or growth hormone deficiency due to actions of the granulomas either in the hypothalamus or pituitary.

Histiocytosis and Eosinophilic Granuloma are rare diseases that can affect the pituitary gland and hypothalamus. They have effects elsewhere in the body, as well. As with sarcoidosis, Diabetes Insipidus is common as is pituitary insufficiency. The disorders themselves are generally treated by specialists for these diseases, while the pituitary issues are managed by neuroendocrinologists.

Pituitary Apoplexy: Pituitary apoplexy is a hemorrhagic disorder of the pituitary. It generally happens in people with pituitary adenomas. It is heralded by a severe headache often together with visual problems. The latter can be double vision or loss of visual fields. Although apoplexy can occur with any sort of pituitary tumor it happens most commonly in non-functioning ones. This is especially true in individuals who were not aware that they had pituitary tumors. A drop in blood pressure can sometimes precede apoplexy. Pituitary apoplexy is a medical emergency. Anyone who develops such symptoms as described above should seek immediate medical attention

6. What is the best treatment for a pituitary tumor?

Pituitary tumors are diagnosed by signs and symptoms, blood tests and X-rays. Depending on the type, size, location, and symptoms, clinical decision must be made as to whether any therapy is necessary and, if so, whether medical, surgical, and radiation therapy alone or in combination are required. In some patients, immediate therapy may not be indicated, in which case it is important to monitor changes in signs and symptoms, blood tests, and X-rays over time.

The best treatment depends on the type of pituitary tumor. Prolactin producing tumors are most successfully treated with medical therapy (pills). In over 90% of patients, medical therapy (pills) reduces tumor size and blood prolactin levels. In approximately 8-10% of patients, medical treatment is not adequately effective and surgery, and rarely, radiation therapy, may be necessary.

The best treatment for other types of pituitary tumors, when surgical treatment is required, is removal of the tumor by an experienced neurosurgeon who performs pituitary surgery frequently. Although most neurosurgeons have some experience with pituitary surgery, only a few have devoted their career to pituitary surgery and have the “best” records of success.

7. If a tumor was successfully removed why are regular visits, blood tests and MRIs necessary?

A minority of patients with pituitary tumors will have a recurrence of the tumor after the initial surgery. Even in the best surgical hands, a significant minority of patients will have a tumor recurrence within 10 years and many will require additional treatment (medical, surgery, pituitary radiation). Since it is not possible to predict which patient’s tumor will recur, all patients need regular medical follow up. Additionally, a tumor may recur 20 years or more after the original treatment. If the tumor was producing a hormone that caused particular symptoms (Cushing’s, Acromegaly, prolactin tumor), the patient is usually the first to recognize this. Measurement of the appropriate hormone level in blood and/or urine is the most accurate method of determining if the tumor has recurred. Non secretory tumors do not produce an excessive hormone that can be measured in the blood or urine and the MRI scan is the best method to follow this condition. In addition, periodic test of normal pituitary function are required in patients with non hormone-secreting tumors as hypopituitarism may be the first sign of tumor regrowth. Furthermore, patients receiving hormone replacement need to be monitored at regular intervals for adequacy of treatment and to learn of the availability of newer forms of therapy.

8. Is radiation necessary in all patients? Who should have radiation treatment to the pituitary?

Radiation to the pituitary is not the first line of treatment for most pituitary tumors. It does not produce an immediate effect to lower excessive hormone production or shrink the tumor. Radiation is used when there is significant tumor remaining after surgery, there are no effective medical therapies for the tumor, or when surgery cannot be performed. Pituitary radiation may take several years to be effective. For example, in patients with acromegaly (excessive growth hormone production), growth hormone levels may remain elevated for 10 to 20 years after conventional radiation.

9. Are all types of pituitary radiation the same?

No. There are different methods of delivering radiation to the pituitary gland. Conventional (fractionated) radiation refers to delivery of a small amount of radiation every day for 4 to 5 weeks. Stereotactic radiation refers to delivery of a precisely focused beam of radiation to the remaining tumor, usually as one treatment (for example, the Gamma Knife, LINEAC, proton beam). The decision as to which type of radiation to administer must be made only after a careful review of the MRI scan to assess the size and location of the residual tumor. A large tumor that is near the optic chiasm (eye nerves) is not suitable for stereotactic radiation because of the intensity (radiation dose) of the single treatment and risk of damage to vision. Stereotactic radiation is reserved for residual tumor that is not near the optic chiasm. Surgery is sometimes needed to remove the portion of the tumor that is near the optic chiasm so that more effective radiation therapy can be given.

10. What are the side effects of radiation?

The most common side effect is loss of normal pituitary function. This may occur within a year or many years after treatment. One study reported that 50% of patients treated with conventional radiation developed deficiency of one or more pituitary hormones within 2 years of treatment. Although development of a pituitary hormone deficiency is not desirable, hormone replacement therapy is available. Every patient treated with radiation, which affects the pituitary or hypothalamus is at risk for the development of loss of pituitary function. Therefore, periodic blood tests are required. An uncommon side effect is damage to vision. In small number of patients, another type tumor, which may be malignant, may develop in the area where radiation was given. Patients receiving conventional radiation may also be at increased for stroke. The risk associated with newer forms of radiation is not yet known. These risks must be weighed against the risk of tumor re-growth. Hair loss does not usually occur.

11. Does a pituitary tumor shorten life?

Having a pituitary tumor should not shorten life if it is properly treated and if the patient receives appropriate hormone replacement(s). In large population studies, it appears that patients who had conventional, radiation for pituitary tumors had an increased mortality (death) risk because of cerebrovascular disease (stroke).

Pituitary hormone deficiency requires hormone(s) replacement. All medications must be taken as directed. Additionally, there is a need for regular medical care and monitoring of medical treatments. Most patients who have had a pituitary tumor engage in normal work and social activities. If a patient requires steroid (cortisol) replacement, a Medical alert bracelet or necklace should be worn at all times. Another illness such as the flu, pneumonia or an accident requires an increase in the steroid dose. If the patient is brought to the hospital and unable to give the medical history, the physicians will have no way of knowing that additional steroid is necessary. With attention to these important details, a patient with a pituitary tumor should have a full and productive life. 

Patients with uncontrolled Acromegaly (growth hormone producing tumor) or Cushing’s disease (excessive cortisol production) do have an increased risk of dying earlier than expected and for having complications of the hormone excess. Lowering of the excessive hormone level to normal reduces this risk. Complications associated with pituitary tumors include:

Acromegaly: heart failure, high blood pressure, abnormal lipids (cholesterol), diabetes, snoring and other sleep-related breathing problems, joint disease, loss of reproductive function, infertility, colon polyps (benign growths) and possibly color cancer.

Cushing’s disease: heart disease, abnormal lipids, diabetes, high blood pressure, osteoporosis and bone fractures, depression and suicide risk, memory loss, muscle weakness, reproductive disorders, infertility, and susceptibility to infection.

Prolactinoma : high prolactin is not known to shorten life; however loss of normal testosterone production in men causes osteoporosis and increases the risk for bone fractures. This also occurs in women who have loss of regular menstrual cycles. Non-functioning adenoma, Craniopharyngioma, Rathke’s Cleft cyst, pituitary cyst: There is no known risk of premature death as long as appropriate hormone replacement(s) are taken. Complications are related to the adequacy of hormone replacement(s).

Posted in FAQ’S | No Comments »

INTRASELLAR PRESSURE AND TUMOR VOLUME IN PITUITARY TUMOR: RELATION STUDY

May 28th, 2008 by admin

Relação entre pressão intra-selar e volume de tumor de hipófise

Jackson A. GondimI; Osvaldo I. Tella Jr.II; Michele SchopsIII

INeurosurgery Department General Hospital of Fortaleza, Fortaleza CE, Brazil
IINeurosurgery Service, Federal University of São Paulo, São Paulo SP, Brazil
IIIFederal University of Ceará, Fortaleza CE, Brazil

ABSTRACT

OBJECTIVE: To determine if there was a relationship between intrassellar pressure (ISP) and pituitary tumor volume.
METHOD: Between August 2002 and May 2004, 60 patients aged between 13 and 75 years old (39 males), having a pituitary adenoma were submitted to an endoscope transseptal approach. During the surgery and before tumor resection, 2 mm of the sellas floor were removed and a 1.5 mm dural opening made to place a transducer into the pituitary adenoma. The transducer was connected to a pressure monitor.
RESULTS: The intrasellar pressure, ranged from 2-51 mmHg and was measured based on the classification of Hardy-Vezina. The most elevated was in the type II macro adenomas with 32.6 mmHg, sharply superior to the value of a normal intracranial pressure.
CONCLUSION: These values showed that the macroadenomas confined to the sella, without destruction of the floor and integrity of the diaphragm, type II of Hardy-Vezina, presented a value of ISP much higher than intra-extrasellar macroadenomas.

Key words: pituitary adenoma, intrasellar pressure, endonasal approach

RESUMO

OBJETIVO: Determinar se existia uma relação entre a pressão intraselar (ISP) e o volume de tumor de hipófise.
MÉTODO: Entre agosto de 2002 e maio de 2004, 60 pacientes com idades variando entre 13 e 75 anos (39 homens), portadores de adenoma hipofisários foram operados por via transesfenoidal. Durante o ato cirúrgico e antes da resseção do tumor, uma osteotomia de 2 mm foi realizada no assoalho selar e uma abertura de 1,5 mm na duramater para a introdução de um transdutor dentro do tumor. O transdutor foi conectado a um monitor de pressão e esta foi medida por 2 minutos.
RESULTADOS: A pressão intra-selar variou entre 2-51 mmHg e a correlação entre tamanho do tumor e ISP foi baseada na classificação de Hardy-Vezina. A média da ISP mais elevada foi encontrada nos macroadenomas tipo II com 32,6 mmHg, nitidamente superior a pressão intra selar normal.
CONCLUSÃO: Estes valores mostram que os macroadenomas confinados a sela sem destruição do assoalho selar e com integridade do diafragma, classificados como tipo II de Hardy-Vezina, apresentam uma ISP muito superior aos outros adenomas.

Palavras-chave: adenoma hipofisário, pressão intra-selar, via transesfenoidal.

There are studies in the literature correlating intrasellar pressure (ISP) and adenoma blood flow1, ISP and stalk compression syndrome2, ISP and endocrine function3,4, ISP and headaches3, pituitary volume and headache5, ISP and pituitary tumor apoplexy6, but there are no specific studies correlating ISP and tumor volume.

The walls of the sella turcica are a relatively rigid structure and under normal circumstances, may serve to protect the pituitary gland from trauma and surrounding pressure fluctuations. The growth of a tumor within the sella, a normally inelastic space, is likely to cause an increase of ISP. It has been conjectured that relatively small increases of ISP may disturb anterior pituitary perfusion and endocrine function because of the low input pressure of the feeding portal veins3. Normal ISP is not known but it is unlikely to exceed normal intracranial pressure (ICP). The ISP has been shown to be elevated in patients with pituitary tumors3. It has been proposed that relatively small increases of ISP may disturb anterior pituitary perfusion. The highest pressures were recorded in tumors with parasellar invasion irrespective of the size and extension and there were no correlation between the level of raised ISP and the tumors size3. Our study, in the contrary, postulates that the highest ISP is found in macroadenomas confined to an enlarged sella without disruption of the floor and with integrity of the diaphragm as type II tumor of Hardy Vezina6.

The objective of this study is to determine if there is a relationship between ISP and pituitary tumor volume.

METHOD

Between August 2002 and May 2004 sixty consecutive patients (39 males) with pituitary adenomas were operated by transnasal transsphenoidal endoscopic surgery and had their ISP measured during surgery for pituitary adenoma at our institution. Their age was between 13 and 75 years old. Among the 60 cases, studied, 42 (70%) were functional adenomas (eighteen producing adrenocorticotropin hormone, fourteen producing growth hormone, six producing prolactine hormone and four cases of plurihormonal adenomas) and eighteen null cells adenomas. All patients were ambulatory. No patients were using glucocorticoids or had pituitary apoplexy, but some patients had adenomas with cystic component. The patients with hormonal hypopituitarism, the compensation usually begins in the transoperative period. The study was approved by the Institutional Review Board of General Hospital of Fortaleza, an informed consent was obtained from each patient.

All patients underwent pituitary computerized tomography (CT) and magnetic resonance image (MRI) at 1.5 T. The MRI examination included coronal and sagittal T1-weighted spin-eco sequences with a maximum section thickness of 3 mm, before and after intravenous administration of a gadolinium-based contrast medium. For the estimation of the tumor volume, it was assumed that the pituitary tumors had an ellipsoid form5,7-9. If the tumor was large and multilobed, the tumor volume was assumed to consist of separated ellipses and the sum of each volume was calculated.

Tumors were subdivided according to radiological classifications of Hardy and Vezina6. The tumors were classified as microadenoma grade 0 where they weren’t visible on imaging. Immunohistochemical characteristics of tumor were available in all patients.

Pre-operative pituitary function evaluation was performed in all patients, and included basal serum free T4, free T3, thyroid stimulation hormone, follicle-stimulating hormone, luteinizing hormone, testosterone (men), cortisol levels on multiple days, adrenocorticotropic hormone, prolactin, growth hormone and somatomedin-C and a glucose tolerance test with GH.

The transsphenoidal exploration was carried out under general anesthesia with normotension and normocapnia. The pituitary sellas floor was exposed through a transnasal transseptal approach assisted by endoscope10. On entering the sphenoid air sinus a 2-mm diameter window of the bone sellas floor was remove and a 1.5 mm dural opening was made to allow the transducer placed into a needle in the tumor mass without extravasation of intrasellar content. Once the transducer placed the needle is taken off and the ISP measured. In some patients with cystic component a careful attention is made for extravasations of tumor component. If there were tumor component extravasations, the ISP measurement would be stopped and the patient wouldn’t count. The fiberoptic transducer is located at the tip and has a 1.3 mm diameter. Sixty seconds later, after a stable pressure obtained, the pressure was recorded, the transducer removed and the tumor resection initiated. We used the Coodman Intracranial Pressure Monitoring Kit (Camino Laboratories San Diego, CA) to determinate the ISP. The kit uses a fiberoptic transducer connected to a pressure monitor.

The statistic analysis was done using the test of Levene to see the homogeneity of variances. The F test was done to know if there was a difference between the five intrasellar pressure median groups. The individual comparisons between the pairs of the five group of ISP were done using the multiple comparasions test of Bonferroni. Statistic analysis using the F test was done with the prolactine medium in each group of patients (Cushing, acromegaly and null cells adenoma). The ISP was also compared into the four group of pathology (acromegaly, Cushing, prolactinoma and nulls cells adenoma). Variables with significant probability values (p<0.05) were considered a possible significant. Statistical evaluation was performed with commercially available statistical software (SPSS version 10.0).

RESULTS

Tumor volume was measured in all adenomas and varied between 0 cm3 (in six patient with clinical and laboratorial diagnosis of Cushing’s disease, but with no radiological image) and 134.5 cm3 in a non-functioning pituitary adenoma with a cystic component. The tumors of this series were solid in 51 patients (85%) and had a cystic component in 9 (15%).

The ISP was measured in all 60 patients and ranged from 2-51 mmHg with mean (±sd) of 18.7±10.8 and a median of 16 mmHg. The test of homogeneity of variances Levene Statistic showed significant (1.639 p=0.178) the amostrage of ISP measurement. The median comparison of the five groups of ISP showed all different (F 17.69 p=0.001). The statistic study was done to known the specific pair-wise analyses and showed that ISP of group 2 of Hardy-Vezina was different in the pair comparison of all other group (0 an2 p=0.026; 1 and 2 p=0.0001, 2 and 3 p=0.0001; 2 and 4 p=0.0001).

Posted in INTRASELLAR PRESSURE AND TUMOR VOLUME IN PITUITARY TUMO | No Comments »

PITUITARY TUMOR

May 28th, 2008 by admin

Acromegaly is a chronic metabolic disorder caused by the presence of too much growth hormone. When this happens, your bones increase in size, including those of your hands, feet and face. Acromegaly affects mostly middle-aged adults. Overproduction of growth hormone is almost always caused by a noncancerous (benign) pituitary tumor (adenoma). This causes abnormal enlargement of bone, cartilage, muscle, organs, and other tissues. Other symptoms of acromegaly include thick, coarse, oily skin; skin tags; enlarged lips, nose and tongue; deepening of the voice due to enlarged sinuses and vocal cords; snoring due to upper airway obstruction; excessive sweating and skin odor; fatigue and weakness; headaches; impaired vision; abnormalities of the menstrual cycle and sometimes breast discharge in women; and impotence in men. The most serious health consequences of acromegaly are diabetes mellitus, hypertension, and increased risk of cardiovascular disease. Patients with acromegaly are also at increased risk for polyps of the colon that can develop into cancer. Acromegaly most commonly affects middle-aged adults and can result in serious illness and premature death. Because of its insidious onset and slow progression, the disease is hard to diagnose in the early stages and is frequently missed for many years.Causes of Acromegaly

The common Causes of Acromegaly :

Acromegaly is caused by prolonged overproduction of GH by the pituitary gland. In about 90% of Acromegaly patients, the overproduction of GH is caused by a benign tumor of the pituitary gland called an adenoma. In a few patients, Acromegaly is caused by tumors of the pancreas, lungs, and adrenal glands. Symptoms of Acromegaly Some Symptoms of Acromegaly : Arthritis and carpal tunnel syndrome.

Diabetes mellitus.

Hypertension.

Macroglossia [enlarged tongue] .

Enlarging hands.

Brow and lower jaw protrusion.

Enlarging feet.

Heart failure.

Treatment of Acromegaly

Radiation therapy has been used both as a primary treatment and combined with surgery or drugs. It is usually reserved for patients who have remnants of the tumor even after surgery. Radiation therapy is given in divided doses over four to six weeks. This treatment lowers GH levels by about 50 percent over 2 to 5 years, but it causes a gradual loss of production of other pituitary hormones. Other rare complications associated with radiation therapy are loss of vision and brain injury.

Somatostatin and dopamine analogues and GH receptor antagonists are the mainstays of medical treatment and are generally used after failure of primary surgery to induce complete remission.

Treatment may include removal of the tumor, radiation therapy, and injection of a growth hormone blocking drug.

Tumors that co-secrete prolactin have a better response rate to dopamine agonists. The response to hese gents is often detected by a trial of the drug in suitable patients.

The goal of treatment is to restore the pituitary gland to normal function, producing normal levels of growth hormone. Microsurgery to remove the pituitary tumor causing this condition corrects the abnormal growth hormone secretion in most patients. This surgery may not be available to patients in isolated geographic locations, so travel to a larger metropolitan area may be necessary for treatment.

Posted in PITUITARY TUMOR-3 | No Comments »

RESULTS OF SOMATOSTATIN RECEPTOR SCINTIGRAPHY DO NOT PREDICT PITUITARY TUMOR VOLUME- AND HORMONE-RESPONSE TO OCREOTIDE THERAPY AND DO NOT CORRELATE WITH TUMOR HISTOLOGY

May 28th, 2008 by admin

Department of Endocrinology, Klinikum Benjamin Franklin, Freie Universitat, Berlin, Germany.

The value of somatostatin receptor scintigraphy (SRS) to predict the effect of somatostatin analog therapy on pituitary adenomas is not clear, due to the use of different radiopharmaceuticals (123I-Tyr3-octreotide and 111In-pentetreotide) and the small number of patients in previous studies. We used 111In-pentetreotide scintigraphy in 49 patients in order to (i) correlate SRS results with basal tumor volume as well as volume- and hormone-response to 3 months of octreotide therapy (Oct-Tx). (ii) identify tumor remnants after incomplete surgery and (iii) evaluate any correlation with immuno histology. Twenty-five patients had a GH-secreting adenoma (GH-A, 15 prior to intended surgery, 10 with persistent/recurrent disease after previous therapy). Twenty-four patients had a clinically non-functioning adenoma (NF-A). For SRS, planar and single photon emission computer tomographic images (SPECT) were recorded 4 h and 24 h post injection. SRS grading was as follows: GO, no uptake: G1, uptake comparable to normal pituitary; G2, increased uptake: G3, very intense uptake. G2/3 was seen in 8/25 GH-A and in 12/24 NF-A. Pretreatment tumor volume (magnetic resonance imaging (MRI) tended to be related to 111In-pentetreotide uptake in GH-A with a tumor visible on MRI (G0/1 (n = 10) vs G2/3 (n = 8): 3.6 +/- 1.9 vs 10.5 +/- 6.5 cm3 (mean +/- S.E.), P = 0.051), but not in NF-A (G0/1 (n = 12) vs G2/3 (n = 12): 17.0 +/- 10.1 vs 14.3 +/- 3.6 cm3). SRS did not identify a tumor remnant in the 7 MRI-negative patients with persistent post-operative acromegaly. Basal GH (6-h profile) and IGF-1 in GH-A did not correlate with SRS results (G0/1 (n = 17) vs G2/3 (n = 8), GH: 32.3 +/- 18.2 vs 29.3 +/- 7.4 micrograms/l IGF-I: 851 +/- 80 vs 1038 +/- 153 micrograms/l). During Oct-Tx of GH-A neither tumor shrinkage nor GH suppression was related to SRS results. In 6 NF-A classified as gonadotropinomas (by their plasma glycoprotein hormone or alpha-subunit concentrations, basally and/or in response to TRH) 111In-pentetreotide uptake was not different from that of the non-gonadotropin/non-secreting adenomas. SRS results were not related to the immunohistological subtype in 22 GH-A (monohormonal mixed somatotrope/lactotrope, plurihormonal) or in 22 NF-A (null-cell adenomas, gonadotropinomas silent hormonal adenomas). We conclude that 111In-pentetreotide SRS reflects tumor volume poorly in GH-A and not at all in NF-A. It does not predict the effect of Oct-Tx on the volume of both GH-A and NF-A, nor on the GH concentration in GH-A. 111In-pentetreotide SRS is unable to identify post-operative tumor remnants not visible on MRI.

Posted in RESULTS OF SOMATOSTATIN RECEPTOR SCINTIGRAPHY DO NOT PR | No Comments »

PITUITARY TUMOR

May 28th, 2008 by admin

There is absolutely no other Squalamine product on the market that matches the ultra purity and potency of this unique and freshly produced product — the one-and-only, original Squalamax™ - Natural Squalamine Extract Capsules. This product originates from God’s amazing medicinal treasure chest, the deep sea. Squalamax™ is naturally rich in squalamine, and is extracted from the livers of deep-water sharks, which inhabit the cold, non-polluted waters off the coast of Newfoundland and other countries. This superior, all-natural, whole shark liver product is minimally processed to ensure that the squalamine component and all of its natural trace elements are maintained. Harsh processing and heat are avoided which would strip the shark livers of many of its valuable natural constituents. It is 100% pure and natural, with no artificial coloring, additives or preservatives. This shark liver product is also environmentally sound as only sharks that are caught as a by-product of deep-sea fishing are used, making a valuable remedy from a natural resource that would have otherwise gone to waste.

What is Squalamine?

Squalamine is not a protein. Instead, it is the first known example of a class of compounds called aminosterols, each a steroid chemically linked to an amino acid. And while proteins make poor drugs, because they are easily destroyed by digestive enzymes in the stomach, squalamine remains unscathed through the digestive tract.

Has research been done on squalamine?

Yes, Squalamine is being investigated by Johns Hopkins School of Medicine researchers, Dr. Henry Brem, Allen Sills, Mark Donowitz and their collaborators for its tumor destroying ability. Squalamine destroyed the tumor spreading ability in rabbits by suppressing the growth of new blood vessels needed to support the growth of tumors. Squalamine halted the growth of brain tumors in rats and prolonged the lives of the laboratory animals. At the 1996 annual meeting of the American Association of Neurological Surgeons in Minneapolis, Dr. Brem commented, “Our findings present evidence that squalamine may work against brain cancer.” Preliminary studies with certain brain cancer cells (glioma) have been encouraging, and the group plans clinical studies by the second half of 1998.


How much Squalamine is in the Squalamax™ product?

Approximately 150ug per gram.

Can I take the Ultramarine Shark Liver Oil Gelcaps product along with the the Squalamax™ product?
Yes, the Ultramarine Shark Liver Oil Gelcaps product contains Squalene, Alkylglycerols (AKG’s), essential fatty acids, and other compounds which enhance the effectiveness of Squalamax™. We suggest you take 2 capsules of each daily, unless your health challenge is more serious.

Angiogenesis is a function in the body where unhealthy cells develop their own blood vessel structure in order to nourish and support themselves (See Figure 1.). The immune system in response uses certain compounds in the body to naturally counter angiogenesis. This normal body function is called anti-angiogenesis. If the immune system is successful in carrying out this designed function of nature, unhealthy cells can not survive. However, if the body is deficient in these vital compounds, anti-angiogenesis can not occur. Therefore, it is important to supplement the body with natural anti-angiogenesis factors such as squalamine which is abundant in the Squalamax™ product.

Posted in PITUITARY TUMOR-2 | No Comments »

DEFINITION

May 28th, 2008 by admin


Posted in DEFINITION | No Comments »

PITUITARY TUMOR (MEDICAL CONDITION)

May 28th, 2008 by admin

Most pituitary tumors are benign. However, because the pituitary is an important hormonal gland, this does not mean they are harmless. Even a benign pituitary tumor can have various severe hormonal affects on the body,

Pituitary tumor: See also Pituitary Cancer:

  »Introduction: Pituitary Cancer

  »Symptoms of Pituitary Cancer

  »Treatments for Pituitary Cancer

Pituitary tumor: Abnormal growth of the cells that comprise the pituitary gland without specification as to whether the cells are malignant or benign.

Source: Diseases Database

Pituitary tumor: Another name for Pituitary Cancer (or close medical condition association).
»Introduction: Pituitary Cancer

  »Symptoms of Pituitary Cancer

  »Treatments for Pituitary Cancer

Pituitary tumor: Pituitary tumor is listed as a type of (or associated with) the following medical conditions in our database: Cancer, Endocrine system cancer, Pituitary conditions

Some of the causes of Pituitary tumor are included in the list below:

*                          Pituitary tumour (growth hormone secreting)

*                          Prolactin secreting pituitary tumour

*                          Cushing’s disease

Read more about causes of Pituitary tumor (Pituitary Cancer)

Some of the symptoms of Pituitary tumor incude:

*                          Headaches

*                          Vision problems

*                          Visual disturbances

*                          Nausea

*                          Vomiting

Treatments for Pituitary tumor (Pituitary Cancer) include:

*                          Surgical removal of the tumor - the most common treatment

*                          Radiation therapy

*                          Drug therapy

*                          Hormone supplements - if the tumor has reduced production of any of the various hormones.

Read more about treatments for Pituitary tumor

Treatment of Pituitary tumor: For more treatment information about Pituitary tumor, see treatment of Pituitary Cancer (Pituitary tumor)

Pituitary tumors are abnormal growths found in the pituitary gland, a small organ–about the size of a dime and located in the center of the brain–which makes hormones that affect growth and the functions of other glands in the body. (Source: excerpt from NINDS Pituitary Tumors Information Page: NINDS)

Posted in PITUITARY TUMOR (MEDICAL CONDITION): | No Comments »

WHAT ARE PITUITARY TUMORS

May 28th, 2008 by admin

Pituitary tumors (adenoma) and the diseases they cause (e.g. acromegaly, Cushing’s disease, hyperprolactinemia). may cause any one or more than one of a number of symptoms (see Pituitary Tumor Symptoms).

      Prolactinoma (benign tumor of the pituitary gland and nonfunctioning pituitary adenoma)

      Acromegaly (Growth hormone secreting adenoma)

      Cushing’s Disease (ACTH secreting adenoma)

      Thyrotropin (TSH) secreting adenomas

      Craniopharyngiomas (intracranial tumors that may involve the pituitary)

Frequently Asked Questions About Radiation Therapy for Pituitary Adenomas

      Brain Injury and Pituitary Dysfunction

      Pituitary Disease in Multiple Endocrine Neoplasia Type 1http://pituitary.mgh.harvard.edu/PituitaryTumors.htm - DiagnosisPlrlactinomas#DiagnosisPlrlactinomas

      Diagnosis and Treatment of Prolactinomas in Men

      Frequently Asked Questions About Transsphenoidal Surgery For Pituitary Adenomas - A Patient Guide

      Cushing’s Disease after Successful Transsphenoidal Surgery - What to Expect and How to Manage

      Technologic Advance: Intraoperative MRI used for Pituitary Tumors at MGH

      Neuroendocrine Complications of Radiation For Non-Pituitary Tumors

      Neurocognitive Dysfunction in Patients with Pituitary Ademomas

      Prolactinomas and Pregnancy

      Stereotactic Proton Irradiation of Pituitary Adenomas

      Pituitary Journal Review: Discussion of Recent Articles of Interest Related to Pituitary Disease

      Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment

      Cabergoline - A New Dopamine Agonist for the Therapy of Prolactinoma

      Headaches and Pituitary Tumors

      Management of Recurrent Pituitary Adenomas

      Common Symptoms of Pituitary Adenomas

      Indications for Treatment of Microprolactinomas: An Update

Clinically Nonfunctioning Pituitary Adenomas: Characterization and Diagnosis

Posted in WHAT ARE PITUITARY TUMORS-1 | No Comments »